Amy L. Hartman, PhD
- PhD, University of Pittsburgh School of Medicine
- BA, Washington and Jefferson College
Assistant Professor, Department of Infectious Diseases and Microbiology, Graduate School of Public Health
Member, Center for Vaccine Research
Assistant Proessor, Department of Microbiology and Molecular Genetics
Member, Graduate Program in Microbiology and Immunology (PMI)
Member, Infectious Diseases and Microbiology Graduate Program
Dr. Hartman's broad research interests center on understanding the pathogenic mechanisms of RNA viruses, particularly arboviruses (viruses transmitted by insect vectors). The focus of her research is on arboviruses that have the potential to spread to new locations (emerging viruses), as well as those that have the potential for misuse through bioterrorism. In addition to understanding the disease-causing mechanisms of these viruses, Dr. Hartman works closely with the Department of Defense to assist in the testing of new treatments and vaccines to protect U.S. military personnel from exposure to virulent viruses. Current research projects in Dr. Hartman's lab focus on aerosol infection models of Rift Valley Fever virus and the alphaviruses (Eastern, Western, and Venezuelan equine encephalitis viruses).
Rift Valley Fever virus (RVFV) is a mosquito-borne virus that causes severe disease in livestock and humans in Africa and the Arabian Peninsula. Rift Valley Fever is found endemically in these regions, and rainfall alterations can lead to epizootics in livestock and epidemics in humans. RVFV is easily transmitted when humans handle infected animal carcasses. Better vaccines and therapeutics for this globally-important emerging infectious disease are needed. Current research projects in Dr. Hartman's lab focus on the neuropathogenesis of RVFV. Dr. Hartman has established the first well-characterized models of the neurological disease that is seen in some RVFV-infected people. These models are currently being used to understand how the virus causes lethal encephalitis. Dr. Hartman's models have also been used to test novel antiviral drugs, such as Favipiravir (T-705), to determine its broad-spectrum applicability to treat emerging diseases.
Albe, J.R., D.A. Boyles, A.W. Walters, M.R. Kujawa, C.M. McMillen, D.S. Reed, and A.L. Hartman. 2019. Neutrophil and macrophage influx into the central nervous system are inflammatory components of lethal Rift Valley Fever encephalitis in rats. PLOS Pathogens. June 20, 2019. 15(6):e1007833. https://doi.org/10.1371/journal.ppat.1007833.
Walters, A.W., M.R. Kujawa, J.R. Albe, W.B. Klimstra, and A.L. Hartman. 2019. Vascular permeability in the brain is a late pathogenic event during Rift Valley fever virus encephalitis in rats. Virology 526:173-179. https://doi.org/10.1016/j.virol.2018.10.021
McMillen, C.M., N. Arora, D.A. Boyles, J.R. Albe, M.R. Kujawa, J.F. Bonadio, C.B. Coyne, and A.L. Hartman. 2018. Rift Valley fever virus induces fetal demise through direct placental infection. Science Advances 4(12):eaau9812. December 5, 2018. http://advances.sciencemag.org/content/4/12/eaau9812.
McMillen, CM, and A.L. Hartman. 2018. Rift Valley fever in animals and humans: Current perspectives. Antiviral Research. 156:29-37. https://doi.org/10.1016/j.antiviral.2018.05.009
Lane WC, Dunn MD, Gardner CL, Lam LKM, Watson AM, Hartman AL, Ryman KD, Klimstra WB. 2018. The efficacy of the interferon alpha/beta response versus arboviruses is temperature dependent. mBio 9:e00535-18. https://doi.org/10.1128/mBio.00535-18